Tickers

1. Composite Trajectory Verdict

The income statement matters most for assessing a health insurer's financial performance because the benefit expense ratio directly reflects underwriting discipline and profitability of the core risk-bearing business.

Composite Trajectory: Mixed

Overall Assessment: The income statement shows deteriorating profitability with net income falling 5.3% to $5,662M and the benefit expense ratio rising 150 bps to 90.0% (10-K 2025, Consolidated Statements of Operations). Operating cash flow declined 26% to $4,290M, the second consecutive annual drop (10-K 2025, Consolidated Statements of Cash Flows). Offsetting these, the balance sheet improved with debt-to-capital falling to 42.1% from 43.0% and shareholders' equity rising 6.3% to $44,026M (10-K 2025, Consolidated Balance Sheets). Revenue grew 12.8% to $197,584M driven by premium rate increases and acquisitions (10-K 2025, MD&A).

2. Red Flags

• Benefit expense ratio increased from 87.0% (2023) to 88.5% (2024) to 90.0% (2025), a 300 bps deterioration over two years, indicating medical cost trends consistently exceeding premium yields (10-K 2025, Consolidated Statements of Operations).
• Operating cash flow fell from $8,061M (2023) to $5,808M (2024) to $4,290M (2025), with the cash conversion ratio (operating cash flow/net income) dropping from 1.35x to 0.76x (10-K 2025, Consolidated Statements of Cash Flows).
• Health Benefits segment operating margin collapsed from 4.6% (2023) to 4.2% (2024) to 2.5% (2025), a 210 bps decline over two years (10-K 2025, Reportable Segments Results of Operations).
• Net losses on financial instruments widened to -$653M in 2025 from -$445M in 2024 (10-K 2025, Consolidated Statements of Operations).
• A $666M Provider Settlement Agreement payment in September 2025 materially reduced operating cash flow and was classified as a non-recurring item, yet similar litigation settlements have occurred in consecutive years (10-K 2025, MD&A Liquidity).
• Effective tax rate dropped to 15.6% in 2025 from 24.5% in 2024 due to a discrete non-operating tax benefit, flattering net income comparison (10-K 2025, Consolidated Statements of Operations).
• Medical claims payable rose 8.5% to $17,084M, outpacing premium revenue growth of 14.2% (10-K 2025, Consolidated Balance Sheets; Consolidated Statements of Operations).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment: Shareholders' net income declined for the second consecutive year to $5,662M in 2025 from $5,980M in 2024 and $5,987M in 2023 (10-K 2025, Consolidated Statements of Operations). The benefit expense ratio worsened to 90.0% in 2025 from 88.5% in 2024 and 87.0% in 2023, driven by higher medical cost trends across all lines of business, principally ACA (10-K 2025, MD&A). Total operating gain fell 8.4% to $7,199M, with Health Benefits operating gain dropping 33.4% to $4,158M and its margin contracting to 2.5% from 4.2% (10-K 2025, Reportable Segments Results of Operations). While total operating revenue grew 12.8% to $197,584M, the increase was largely offset by a 16.2% rise in benefit expense to $148,223M (10-K 2025, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Overall Assessment: Net cash provided by operating activities declined 26% to $4,290M in 2025 from $5,808M in 2024, marking the second consecutive annual decrease after $8,061M in 2023 (10-K 2025, Consolidated Statements of Cash Flows). The decline was driven by the $666M Provider Settlement Agreement payment, unfavorable working capital impacts, and lower net income (10-K 2025, MD&A Liquidity). Operating cash flow covered only 76% of net income in 2025 versus 97% in 2024 and 135% in 2023. Investing cash outflows decreased to $1,344M from $5,167M due to absence of acquisitions, while financing activities used $1,738M versus providing $1,193M in 2024, reflecting lower debt issuance (10-K 2025, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Overall Assessment: Shareholders' equity increased 6.3% to $44,026M at December 31, 2025 from $41,426M a year earlier, while the consolidated debt-to-capital ratio improved to 42.1% from 43.0% (10-K 2025, Consolidated Balance Sheets; MD&A Capital Resources). Cash and cash equivalents rose 14.5% to $9,491M, and short-term borrowings fell to $150M from $365M (10-K 2025, Consolidated Balance Sheets). Total assets grew 3.9% to $121,494M, with goodwill stable at $28,344M and other intangible assets declining to $11,200M from $12,094M (10-K 2025, Consolidated Balance Sheets). Medical claims payable increased 8.5% to $17,084M, consistent with premium growth (10-K 2025, Consolidated Balance Sheets).

6. Data Gaps

• Quarterly financial statements for 2026 (Q1, Q2) and comparable 2025 quarters to assess intra-year trends.
• Segment-level quarterly operating revenue and operating gain to evaluate CarelonRx and Carelon Services trajectory.
• Detailed breakdown of "unfavorable working capital impacts" cited as reducing operating cash flow.
• Projected impact of OBBBA Medicaid provisions effective 2027-2028 on future benefit expense ratios.
• RADV audit exposure quantification beyond the disclosed CMS announcement.
• Standalone Q4 2025 results (not separately filed) to isolate fourth-quarter performance.
• Free cash flow metric (operating cash flow minus capital expenditures) not explicitly presented.